Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial
Endang Rahayu Sedyaningsih, Moh Suhud Malik, Vivi Setiawaty, Trihono Trihono, Erlina Burhan, Tjandra Yoga Aditama, Prijanti Z Soepandi, Lia G Partakusuma, Agung P Sutiyoso, Ika Priatni, Hadi Jusuf, Emmy Hermiyanti Pranggono, Arto Yuwono Soeroto, Djatnika Setiabudi, Dadang Hudaya Somasetia, Sri Sudarwati, Tini T Maskoen, Yovita Hartantri, Ida Parwati, Sardikin Giriputro Show all
BMJ (Online) | BMJ PUBLISHING GROUP | Published : 2013
OBJECTIVE: To investigate the validity of recommendations in treatment guidelines to use higher than approved doses of oseltamivir in patients with severe influenza. DESIGN: Double blind randomised trial. SETTING: Thirteen hospitals in Indonesia, Singapore, Thailand, and Vietnam. PARTICIPANTS: Patients aged ≥ 1 year admitted to hospital with confirmed severe influenza. INTERVENTIONS: Oral oseltamivir at double dose (150 mg twice a day/paediatric equivalent) versus standard dose (75 mg twice a day/paediatric equivalent). MAIN OUTCOME MEASURE: Viral status according to reverse transcriptase polymerase chain reaction (RT-PCR) for influenza RNA in nasal and throat swabs on day five. RESULTS: Of ..View full abstract
The study was conducted by the South East Asia Infectious Diseases Clinical Research Network (www.seaicrn.org/) and supported by the National Institute of Allergy and Infectious Diseases and the Wellcome Trust of Great Britain. The Singapore site was supported by the Singapore National Medical Research Council.